	RCE/163k
Application Number: 08/765;026	# #
Filing Date: January 29, 2001	오 _ 문
First Named Inventor: Martine BARKATS et al.	AR C
Group Art Unit: 1636	
Examiner: D. Guzo	VEL 1600/290
Attorney Docket Number: 03804.0118	2/290
Attorney Customer Number: 22,852	0

			` · · ~	H CAN			
REQUEST FOR CONTINUED EXAMINATION (RCE)			REQ	UEST FOR ST	Filing Date: January 29, 2001		
CONTINUED EXAMINATION (RCE) TRANSMITTAL					First Named Inventor: Martine BARKATS et al.		
	G				Group Art Unit: 1636		
	provides for continuous examination of a dainty of plant application			nination of a utility or plant application	Examiner: D. Guzo		
	filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA) Att				Attorney Docket Number: 03804.0118		
					Attorney Customer Number: 22,852		
This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.							
Note: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) instead of a RCE to be eligible for patent term adjustment provisions of the AIPA. See "Changes to Application Examination and Provisional Application Practice," Interim Rule, 65 Fed. Reg. 14865 (March 20, 2000). Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.							
1.	Sul	omis	sion required	under 37 C.F.R. § 1.114:	#.37		
	a. Previously submitted						
		i.		Consider the amendment(s)/reply	after final under 37 C.F.R. § 1.116 previously filed on [Date]		
		ii.		Consider the arguments in the App	peal Brief of Reply Brief previously filed on [Date]		
		iii.		Other			
	b.	\boxtimes	Enclosed:				
		i.	\boxtimes	Amendment/Reply			
		ii.		Affidavit(s)/Declaration(s)			
		iii.		Information Disclosure Statement			
		iv.		Other			
2.	2. Miscellaneous						
	a.		Suspension of action on the above-mentioned application is requested under 37 C.F.R. § 1.103(c) for a period of				
			[number] months. (Period of suspension shall not exceed 3 months; fee under 37 C.F.R. § 1.17(i) required.)				
	b.	Ш	Other				
3. Fees							
	a.	\boxtimes	The filing fee	e is calculated as follows:			
		i.	\boxtimes	\$740.00 RCE fee required under 3	37 C.F.R. § 1.17(e)		
		ii. Petition for extension of time for (3 Months) \$920.00					
		iii.		Other			
	b.	\boxtimes	Check in the	amount of \$1,660.00 enclosed.			
	C.	\boxtimes	The Director is authorized to charge any deficiencies in the filing fees, or credit any overpayments to Deposit Account No. 06-0916.				
Signature of Applicant, Attorney, or Agent Required							
Nar	Name: Charles D. Niebylski Reg. No.: 46,116						
Signature: Date: Λ				100	Date: Murch 21, 2002		
Certificate of Mailing or Transmission							
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, BOX RCE, Washington, D.C. 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on: [Date]							
<u> 1</u>	건키2060년 CRBUYEN 00000009 08765026						
გig nag ire: 740.00 GP D				740.00 OP	Date:		

03 28 01 F





Attorney Docket 50. 03804.0118

MAR 2

IN THE UNITED STATES PATENT AND TRADEMARK OFF

In re Application of:

Martine BARKATS et al.

Serial No.: 08/765,026

Filed: January 29, 2001

For: ADENOVIRUS INCLUDING A

GENE CODING FOR A SUPEROXIDE DISMUTASE

Box RCE

Assistant Commissioner for Patents Washington, DC 20231

Group Art Unit: 1636

Examiner: D. Guzo

#31D

3.28 02

Sir:

SUBMISSION UNDER 37 C.F.R. § 1.114

In reply to the final Office Action mailed on September 25, 2001, Applicants file a Request for Continued Examination and submit the following amendment and arguments in accordance with the requirements of 37 C.F.R. § 1.114. By virtue of the concurrently-filed Petition for a Three-Month Extension of Time and appropriate fee, this Request for Continued Examination and Amendment and Request for Reconsideration are due by March 25, 2002, and are timely filed.

<u>AMENDMENT</u>

IN THE CLAIMS:

Please cancel claims 76, 77, and 80, without prejudice or disclaimer, and amend claims 47, 62, 68, and 81 as follows:

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com